| Oct 9 |
BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2
|
| Oct 7 |
BioCryst (BCRX) Upgraded to Buy: Here's Why
|
| Oct 3 |
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 2 |
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
|
| Oct 2 |
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
|
| Oct 1 |
BioCryst Secures Major US Health Department Influenza Drug Deal
|
| Oct 1 |
BioCryst secures $69m contract from US to supply RAPIVAB for influenza
|
| Sep 30 |
BioCryst Pharmaceuticals awarded $69M influenza treatment contract from U.S. HHS
|
| Sep 30 |
With 80% institutional ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a favorite amongst the big guns
|
| Sep 30 |
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
|
